A matching-adjusted indirect comparison (MAIC) of the efficacy and safety of acalabrutinib (acala) versus zanubrutinib (zanu) in relapsed or refractory chronic lymphocytic leukemia (RR CLL)

被引：0
|
作者：
Kittai, Adam
Skarbnik, Alan
Miranda, Miguel
Yong, Alan S. M.
Roos, Jack
Hettle, Robert
Palazuelos-Munoz, Sarah
Shetty, Vikram
Ghia, Paolo
机构：
[1] Ohio State Univ, Ctr Comprehens Canc, Div Hematol, Columbus, OH 43210 USA
[2] Novant Hlth Canc Inst, Charlotte, NC USA
[3] AstraZeneca, Cambridge, England
[4] AstraZeneca, Wilmington, DE USA
[5] Univ Vita Salute San Raffaele, Milan, Italy
[6] IRCCS Osped San Raffaele, Milan, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7540
引用
下载
收藏
页数：1
相关论文
共 50 条
  • [21] Indirect comparisons of efficacy of zanubrutinib versus orelabrutinib in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma or relapsed or refractory mantle cell lymphoma
    Yuqin Song
    Keshu Zhou
    Shenmiao Yang
    Jianda Hu
    Dehui Zou
    Sujun Gao
    Ling Pan
    Tingyu Wang
    Haiyan Yang
    Huilai Zhang
    Daobin Zhou
    Jie Ji
    Wei Xu
    Ru Feng
    Jie Jin
    Fangfang Lv
    Haiwen Huang
    Xiaosi Fan
    Sheng Xu
    Jun Zhu
    Investigational New Drugs, 2023, 41 : 606 - 616
  • [22] Comparative Efficacy of Ibrutinib Versus Obinutuzumab + Chlorambucil in First-Line Treatment of Chronic Lymphocytic Leukemia: A Matching-Adjusted Indirect Comparison
    Suzy Van Sanden
    Simona Baculea
    Joris Diels
    Sarah Cote
    Advances in Therapy, 2017, 34 : 1650 - 1661
  • [23] Phase 2 study of acalabrutinib in ibrutinib (IBR)-intolerant patients (pts) with relapsed/refractory (RR) chronic lymphocytic leukemia (CLL).
    Rogers, Kerry Anne
    Thompson, Philip A.
    Allan, John Nathan
    Coleman, Morton
    Sharman, Jeff Porter
    Cheson, Bruce D.
    Izumi, Raquel
    Frigault, Melanie M.
    Quah, Cheng Seok
    Raman, Rakesh K.
    Wang, Min Hui
    Kipps, Thomas J.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [24] Comparative Efficacy of Ibrutinib Versus Obinutuzumab plus Chlorambucil in First-Line Treatment of Chronic Lymphocytic Leukemia: A Matching-Adjusted Indirect Comparison
    Van Sanden, Suzy
    Baculea, Simona
    Diels, Joris
    Cote, Sarah
    ADVANCES IN THERAPY, 2017, 34 (07) : 1650 - 1661
  • [25] Long-term safety profile of adalimumab versus ustekinumab in psoriasis: A real world matching-adjusted indirect comparison (MAIC)
    Wu, Jashin J.
    Singh, Rakesh
    Yang, Min
    Li, Junlong
    Bereswill, Mareike
    Garcia-Horton, Viviana
    Valdecantos, Wendell
    Arikan, Dilek
    Weiss, Stefan
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB235 - AB235
  • [26] Matching-adjusted indirect comparisons (MAIC) of safety between single-agent belantamab mafodotin versus selinexor plus dexamethasone in relapsed/refractory multiple myeloma (RRMM)
    Suvannasankha, A.
    Prawitz, T.
    Kapetanakis, V.
    Sarri, G.
    Hughes, R.
    Wang, F.
    Hogea, C.
    Ferrante, S. Allen
    Gutierrez, B.
    Gorsh, B.
    Willson, J.
    Popat, R.
    ANNALS OF ONCOLOGY, 2020, 31 : S654 - S654
  • [27] Efficacy and safety of zanubrutinib versus rituximab-based chemoimmunotherapy in Waldenstrom macroglobulinemia (WM): Matching-adjusted indirect comparisons.
    Castillo, Jorge J.
    Yang, Keri
    Liu, Rongzhe
    Wang, Yu
    Cohen, Aileen
    Zimmerman, Todd M.
    Zhao, Qian
    Gao, Xin
    Tang, Boxiong
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [28] Matching-Adjusted Indirect Comparison of Blinatumomab vs. Inotuzumab Ozogamicin for Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia
    Song, Jinlin
    Ma, Qiufei
    Gao, Wei
    Cong, Ze
    Xie, Jipan
    Zimmerman, Zachary
    Belton, Laura
    Franklin, Janet
    Palmer, Stephen
    ADVANCES IN THERAPY, 2019, 36 (04) : 950 - 961
  • [29] Matching-Adjusted Indirect Comparison of Blinatumomab vs. Inotuzumab Ozogamicin for Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia
    Jinlin Song
    Qiufei Ma
    Wei Gao
    Ze Cong
    Jipan Xie
    Zachary Zimmerman
    Laura Belton
    Janet Franklin
    Stephen Palmer
    Advances in Therapy, 2019, 36 : 950 - 961
  • [30] Pirtobrutinib versus venetoclax in covalent Bruton tyrosine kinase inhibitor-pretreated chronic lymphocytic leukemia: a matching-adjusted indirect comparison
    Al-Sawaf, Othman
    Jen, Min-Hua
    Hess, Lisa M.
    Zhang, Jiewen
    Goebel, Benjamin
    Pagel, John M.
    Abhyankar, Sarang
    Davids, Matthew S.
    Eyre, Toby A.
    HAEMATOLOGICA, 2024, 109 (06) : 1866 - 1873
12345